Bristol Myers Squibb to showcase data across its innovative cardiovascular portfolio at the European Society of Cardiology Congress 2023

Bristol Myers Squibb announced the presentation of research reinforcing the strength of its robust cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place in-person and virtually August 25-28, 2023. Data from clinical studies will be featured, including presentations of Camzyos (mavacamten) cumulative analysis up to 120-weeks and impact to standard of care (SOC) medication from the EXPLORER cohort of the MAVA-long-term extension (LTE) study, as well as a late-breaking presentation of VALOR-HCM-LTE 56-week data, and new data from health economics outcomes research. The Bristol Myers Squibb-Pfizer Alliance will also share an observational retrospective real-world study on the clinical impact of switching or continuation of Eliquis (apixaban) or rivaroxaban among patients with non-valvular atrial fibrillation (NVAF).

“This year’s ESC Congress provides the opportunity to present new data spanning our cardiovascular portfolio, reinforcing our ambition of bringing innovative and life-changing medicines to patients living with cardiovascular diseases,” said Roland Chen, MD, senior vice president and head of cardiovascular & neuroscience development, global drug development. “These data demonstrate the consistency and impact of our cardiovascular medicines – ranging from treatments that have been available to patients with atrial fibrillation for over a decade to our more recent therapeutic option tackling symptomatic obstructive hypertrophic cardiomyopathy.”

Key presentations include:

A late-breaking oral presentation of data from the 56-week VALOR-HCM-LTE study evaluating Camzyos in severely symptomatic obstructive hypertrophic cardiomyopathy patients eligible for septal reduction therapy (SRT).

An updated cumulative analysis of the EXPLORER cohort of the MAVA-LTE study analyzing treatment with Camzyos for up to 120 weeks.

An exploratory analysis from the EXPLORER cohort of MAVA-LTE investigating the effect of changes in SOC medication on the efficacy and safety of Camzyos.

An observational retrospective real-world data study of the clinical impact of switching or continuation of initial Eliquis or rivaroxaban treatment on the risk of stroke/systemic embolism and major bleeding in patients with NVAF.

Camzyos (mavacamten) is the first and only cardiac myosin inhibitor approved in the US, indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms, and in the European Union, indicated for the treatment of symptomatic (NYHA, class II-III) obstructive HCM in adult patients. It has also received regulatory approvals in Australia, Brazil, Canada, Great Britain, Macau, Singapore, South Korea, and Switzerland. Camzyos is an allosteric and reversible inhibitor selective for cardiac myosin. Camzyos modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation. Excess myosin actin cross-bridge formation and dysregulation of the super-relaxed state are mechanistic hallmarks of HCM. Camzyos shifts the overall myosin population towards an energy-sparing, recruitable, super-relaxed state. In HCM patients, myosin inhibition with Camzyos reduces dynamic left ventricular outflow tract (LVOT) obstruction and improves cardiac filling pressures.

Eliquis is an oral selective Factor Xa inhibitor. By inhibiting Factor Xa, a key blood clotting protein, Eliquis decreases thrombin generation and blood clot formation. Eliquis is approved for multiple indications in the US based on efficacy and safety data from multiple phase 3 clinical trials. Eliquis is a prescription medicine indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF); for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery; for the treatment of DVT and PE; and to reduce the risk of recurrent DVT and PE, following initial therapy. Eliquis continues to be developed and commercialized by The Bristol Myers Squibb-Pfizer Alliance.

Eliquis is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Eliquis is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

The Bristol Myers Squibb-Pfizer Alliance (the Alliance) is committed to driving education and awareness about atrial fibrillation and deep vein thrombosis (DVT) and/or pulmonary embolism (PE). With long-standing cardiovascular leadership, global scale and expertise in this field, the Alliance strives to implement global, research-driven approaches to illuminate and address the unmet needs around strokes related to non-valvular atrial fibrillation, which are often fatal or debilitating. Through collaborations with non-profit organizations, the Alliance aims to provide patients, healthcare professionals and decision makers with the information they need to understand and take appropriate action on risk factors associated with stroke and other cardiovascular conditions.

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!